Arovella Therapeutics Ltd has released a press release.
Prospectus For Renounceable Pro Rata Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Rights Issue To Raise Up To $3.44 Million
- Product Development Market Update
- ArTiMist Regulatory Update
- Appendix 4C Amended
- SUDA Signs Agreement With Mitsubishi Tanabe
Later from Arovella Therapeutics
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Rights Issue Closes Significantly Oversubscribed
- Supplementary Prospectus
- European Anagrelide Cancer Patent
- ZolpiMist Clinical Results Published
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics